Literature DB >> 29594409

The optimal TSH level necessary for successful radioiodine ablation of differentiated thyroid carcinoma, as well as the time to reach this level, is a work in progress.

Ismaheel O Lawal1, Mariza Vorster1, Alfred O Ankrah1,2, Mike M Sathekge3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29594409     DOI： 10.1007/s00259-018-3999-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  9 in total

1.  In Patients With Low- to Intermediate-Risk Thyroid Cancer, a Preablative Thyrotropin Level of 30 μIU/mL Is Not Adequate to Achieve Better Response to 131I Therapy.

Authors:  Teng Zhao; Jun Liang; Zhenqing Guo; Tianjun Li; Yansong Lin
Journal:  Clin Nucl Med       Date:  2016-06       Impact factor: 7.794

2.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.

Authors:  David S Cooper; Gerard M Doherty; Bryan R Haugen; Bryan R Hauger; Richard T Kloos; Stephanie L Lee; Susan J Mandel; Ernest L Mazzaferri; Bryan McIver; Furio Pacini; Martin Schlumberger; Steven I Sherman; David L Steward; R Michael Tuttle
Journal:  Thyroid       Date:  2009-11       Impact factor: 6.568

3.  Homeostatic equilibria between free thyroid hormones and pituitary thyrotropin are modulated by various influences including age, body mass index and treatment.

Authors:  Rudolf Hoermann; John E M Midgley; Adrienne Giacobino; Walter A Eckl; Hans Günther Wahl; Johannes W Dietrich; Rolf Larisch
Journal:  Clin Endocrinol (Oxf)       Date:  2014-07-07       Impact factor: 3.478

4.  Higher preablative serum thyroid-stimulating hormone level predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma.

Authors:  Ismaheel O Lawal; Nozipho E Nyakale; Lerwine M Harry; Thabo Lengana; Neo P Mokgoro; Mariza Vorster; Mike M Sathekge
Journal:  Nucl Med Commun       Date:  2017-03       Impact factor: 1.690

5.  The thyroid axis 'setpoints' are significantly altered after long-term suppressive LT4 therapy.

Authors:  F A Verburg; U Mäder; I Grelle; T J Visser; R P Peeters; J W A Smit; C Reiners
Journal:  Horm Metab Res       Date:  2014-05-27       Impact factor: 2.936

6.  Could short thyroid hormone withdrawal be an effective strategy for radioiodine remnant ablation in differentiated thyroid cancer patients?

Authors:  Arnoldo Piccardo; Matteo Puntoni; Giulia Ferrarazzo; Luca Foppiani; Gianluca Bottoni; Vania Altrinetti; Giorgio Treglia; Mehrdad Naseri; Bassam Dib; Manlio Cabria; Pierpaolo Trimboli; Michela Massollo; Luca Giovanella
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236

7.  Endogenous TSH levels at the time of 131I ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality.

Authors:  Alexis Vrachimis; Burkhard Riemann; Uwe Mäder; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-23       Impact factor: 9.236

8.  Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine.

Authors:  C J Edmonds; S Hayes; J C Kermode; B D Thompson
Journal:  Br J Radiol       Date:  1977-11       Impact factor: 3.039

9.  Is Very High Thyroid Stimulating Hormone Level Required in Differentiated Thyroid Cancer for Ablation Success?

Authors:  Zekiye Hasbek; Bülent Turgut
Journal:  Mol Imaging Radionucl Ther       Date:  2016-06-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.